Dr. Rafi Hofstein, president and CEO of MaRS Innovation (right) attends a reception in Israel with Ontario Premier Kathleen Wynne and Dr. Jason Field, president and CEO of Life Sciences Ontario.
“BioLineRx has a proven track record of identifying promising early stage biomedical projects and successfully developing them through clinical stages,” stated Dr. Raphael Hofstein, president and CEO, MaRS Innovation. “We believe that the combination of our pool of novel technologies and projects together with BioLineRx’s drug development expertise and strategic collaborations with global players is a perfect match.”
Parimal Nathwani, MaRS Innovation’s vice-president, life sciences, is also part of Ontario’s life sciences delegation.
About MaRS Innovation
MaRS Innovation (MI) is the commercialization agent for 15 of Ontario’s leading academic institutions. It provides investors and licensees with a single point to access the technology assets emerging from MI’s members, who receive $1.47 billion in annual research and development funding. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its members, MI is a transformational partnership that turns research strengths into commercial opportunities through industry partnerships, licensing and company creation. Follow us on Twitter @marsinnovation.
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx’s leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2 study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently signed a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2 study in pancreatic cancer using the combination of BL-8040 and Merck’s KEYTRUDA®.